Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Zerumbone Sensitizes the Anti-Cancer Efficacy of Cisplatin in Hepatocellular Carcinoma Cells

Author(s): Srimathi Devi Jegannathan, Santhosh Arul and Haripriya Dayalan*

Volume 22, Issue 16, 2022

Published on: 24 March, 2022

Page: [2885 - 2895] Pages: 11

DOI: 10.2174/1871520622666220324090801

Price: $65

Abstract

Background: Zerumbone (ZER) exerts potent antiproliferative, apoptotic, and antiangiogenic functions against variety of cancer cells. Cisplatin (CIS), a standard chemotherapeutic drug, is effective against different types of cancers. However, the combined effect of ZER and CIS on hepatocellular carcinoma remains unknown.

Objective: The present study is attempted to examine the effectiveness of the combination of ZER and CIS in liver cancer in vitro using the hepatocellular carcinoma Huh-7 cell line.

Methods: Effect of ZER, CIS, and their combination therapy on cell viability and cytotoxicity was assessed by MTT and LDH leakage assays. Cell cycle and apoptosis analysis were performed by flow cytometry. Quantitative real-time PCR was used to examine the m-RNA expression of genes involved in apoptosis, angiogenesis, and invasion. Caspase activity was studied using commercial kit method in the Huh-7 cell line.

Results: Cells exposed to ZER, CIS individually, and both together significantly inhibited cell proliferation with IC50 values of 10 μM for ZER and 3 μM for CIS. The combination treatment of ZER and CIS revealed a synergistic effect with a CI value < 1. CIS treatment, either alone or in combination with ZER, caused cell cycle arrest in the S phase. More importantly, ZER combined with CIS exhibited synergistic effects in up-regulating Bax/Bcl-2 ratio, leading to caspase cascade activation.

Conclusion: In conclusion, the current study indicates that the treatment of 4.62 μM of ZER combined with 1.93 μM of CIS in human liver cancer cells exerts synergistic effects on cell growth inhibition, apoptosis induction, angiogenesis, and invasion by modulating gene expression.

Keywords: Apoptosis, cell cycle, cisplatin, combination therapy, liver cancer, zerumbone.

« Previous Next »
Graphical Abstract

[1]
Sung, H.; Ferlay, J.; Soerjomataram, I.; Seigal, R.L.; Toree, L.A.; Jemel, A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2020, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492]
[2]
Aldossary, S.A. Review on the pharmacology of cisplatin: Clinical use, toxicity, and mechanism of resistance of cisplatin. Biomed. Pharmacol. J., 2019, 12(1), 7-15.
[http://dx.doi.org/10.13005/bpj/1608]
[3]
Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol., 2014, 740, 364-378.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[4]
Dev, S. Studies in sesquiterpenes-XVI: Zerumbone, a monocyclic sesquiterpene ketone. Tetrahedron, 1960, 8(3-4), 171-180.
[http://dx.doi.org/10.1016/0040-4020(60)80027-0]
[5]
Redondo-Blanco, S.; Fernández, J.; Gutiérrez-Del-Río, I.; Villar, C.J.; Lombó, F. New insights toward colorectal cancer chemotherapy using natural bioactive compounds. Front. Pharmacol., 2017, 8, 109.
[http://dx.doi.org/10.3389/fphar.2017.00109] [PMID: 28352231]
[6]
Girisa, S.; Shabnam, B.; Monisha, J.; Fan, L.; Halim, C.E.; Arfuso, F.; Ahn, K.S.; Sethi, G.; Kunnumakkara, A.B. Potential of zerumbone as an anti-cancer agent. Molecules, 2019, 24(4), 734.
[http://dx.doi.org/10.3390/molecules24040734] [PMID: 30781671]
[7]
Singh, C.K.; George, J.; Ahmad, N. Resveratrol-based combinatorial strategies for cancer management. Ann. N. Y. Acad. Sci., 2013, 1290(1), 113-121.
[http://dx.doi.org/10.1111/nyas.12160] [PMID: 23855473]
[8]
Gupta, S.C.; Kannappan, R.; Reuter, S.; Kim, J.H.; Aggarwal, B.B. Chemosensitization of tumors by resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215(1), 150-160.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05852.x] [PMID: 21261654]
[9]
Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. Cancers (Basel), 2014, 6(3), 1769-1792.
[http://dx.doi.org/10.3390/cancers6031769] [PMID: 25198391]
[10]
Murakami, A.; Takahashi, M.; Jiwajinda, S.; Koshimizu, K.; Ohigashi, H. Identification of zerumbone in Zingiber zerumbet smith as a potent inhibitor of 12-O-tetradecanoylphorbol-13-acetate-induced epstein-barr virus activation. Biosci. Biotechnol. Biochem., 1999, 63(10), 1811-1812.
[http://dx.doi.org/10.1271/bbb.63.1811] [PMID: 10586508]
[11]
Murakami, A.; Miyamoto, M.; Ohigashi, H. Zerumbone, an anti-inflammatory phytochemical, induces expression of proinflammatory cytokine genes in human colon adenocarcinoma cell lines. Biofactors, 2004, 21(1-4), 95-101.
[http://dx.doi.org/10.1002/biof.552210118] [PMID: 15630177]
[12]
Ahmad, B.A.; Siddig, I.; Al-Zubairi, A.S.; Manal, M.E.T.; Shyam, M.M. Zerumbone: A natural compound with anti-cholinesterase activity. Am. J. Pharmacol. Toxicol., 2008, 3, 206-208.
[13]
Abdelwahab, S.I.; Abdul, A.B.; Devi, N.; Taha, M.M.; Al-zubairi, A.S.; Mohan, S.; Mariod, A.A. Regression of cervical intraepithelial neoplasia by zerumbone in female Balb/c mice prenatally exposed to diethylstilboestrol: Involvement of mitochondria-regulated apoptosis. Exp. Toxicol. Pathol., 2010, 62(5), 461-469.
[http://dx.doi.org/10.1016/j.etp.2009.06.005] [PMID: 19581075]
[14]
Taha, M.M.; Abdul, A.B.; Abdullah, R.; Ibrahim, T.A.T.; Abdelwahab, S.I.; Mohan, S. Potential chemoprevention of diethylnitrosamine-initiated and 2-acetylaminofluorene-promoted hepatocarcinogenesis by zerumbone from the rhizomes of the subtropical ginger (Zingiber zerumbet). Chem. Biol. Interact., 2010, 186(3), 295-305.
[http://dx.doi.org/10.1016/j.cbi.2010.04.029] [PMID: 20452335]
[15]
Plaimee, P.; Weerapreeyakul, N.; Barusrux, S.; John, N.P. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif., 2015, 48(1), 67-77.
[http://dx.doi.org/10.1111/cpr.12158] [PMID: 25580987]
[16]
Jegannathan, S.D.; Arul, S.; Dayalan, H. Zerumbone, a sesquiterpene, controls proliferation and induces cell cycle arrest in human laryngeal carcinoma cell line, Hep-2. Nutr. Cancer, 2016, 68(5), 865-872.
[http://dx.doi.org/10.1080/01635581.2016.1159701] [PMID: 27045964]
[17]
Sakinah, S.A.; Alwi, S.S.; Meenakshi, N.; Hawariah, A. Zerumbone exerts anti-proliferative activity via apoptosis on HepG2 cells. Malaysian. J. Biochem. Mol. Biol., 2006, 15(1), 19-23.
[18]
Arantes-Rodrigues, R.; Pinto-Leite, R.; Fidalgo-Gonçalves, L.; Palmeira, C.; Santos, L.; Colaço, A.; Oliveira, P. Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines. BioMed Res. Int., 2013, 2013, 791406.
[http://dx.doi.org/10.1155/2013/791406] [PMID: 24369536]
[19]
Kielbik, M.; Krzyzanowski, D.; Pawlik, B.; Klink, M. Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells. Oncotarget, 2018, 9(28), 19847-19860.
[http://dx.doi.org/10.18632/oncotarget.24884] [PMID: 29731988]
[20]
Drent, M.; Cobben, N.A.M.; Henderson, R.F.; Wouters, E.F.; van Dieijen-Visser, M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur. Respir. J., 1996, 9(8), 1736-1742.
[http://dx.doi.org/10.1183/09031936.96.09081736] [PMID: 8866602]
[21]
Zaidieh, T.; Smith, J.R.; Ball, K.E.; An, Q. ROS as a novel indicator to predict anticancer drug efficacy. BMC Cancer, 2019, 19(1), 1224.
[http://dx.doi.org/10.1186/s12885-019-6438-y] [PMID: 31842863]
[22]
Wagner, J.M.; Karnitz, L.M. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol. Pharmacol., 2009, 76(1), 208-214.
[http://dx.doi.org/10.1124/mol.109.055178] [PMID: 19403702]
[23]
Wang, P.; Cui, J.; Wen, J.; Guo, Y.; Zhang, L.; Chen, X. Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol. Lett., 2016, 12(6), 4605-4612.
[http://dx.doi.org/10.3892/ol.2016.5288] [PMID: 28105167]
[24]
Zhang, G.; Gurtu, V.; Kain, S.R.; Yan, G. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques, 1997, 23(3), 525-531.
[http://dx.doi.org/10.2144/97233pf01] [PMID: 9298227]
[25]
Kulsoom, B.; Shamsi, T.S.; Afsar, N.A.; Memon, Z.; Ahmed, N.; Hasnain, S.N. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: Are we ready for Bcl-2-directed therapy? Cancer Manag. Res., 2018, 10, 403-416.
[http://dx.doi.org/10.2147/CMAR.S154608] [PMID: 29535553]
[26]
Lv, T.; Zhang, W.; Han, X. Zerumbone suppresses the potential of growth and metastasis in hepatoma HepG2 cells via the MAPK signaling pathway. Oncol. Lett., 2018, 15(5), 7603-7610.
[http://dx.doi.org/10.3892/ol.2018.8335] [PMID: 29849796]
[27]
Takada, Y.; Murakami, A.; Aggarwal, B.B. Zerumbone abolishes NF-kappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene, 2005, 24(46), 6957-6969.
[http://dx.doi.org/10.1038/sj.onc.1208845] [PMID: 16007145]
[28]
Lee, H.; Jeong, A.J.; Ye, S.K. Highlighted STAT3 as a potential drug target for cancer therapy. Biochem. Mol. Biol. Rep., 2019, 52(7), 415-423.
[http://dx.doi.org/10.5483/BMBRep.2019.52.7.152] [PMID: 31186087]
[29]
Hin Tang, J.J.; Hao Thng, D.K.; Lim, J.J.; Toh, T.B. JAK/STAT signaling in hepatocellular carcinoma. Hepat. Oncol., 2020, 7(1), HEP18.
[http://dx.doi.org/10.2217/hep-2020-0001] [PMID: 32273976]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy